Breaking! Harvard and Dana Farber Discover “Gene Signature” of Women Who “Resist” Common Chemotherapy

Richard Saltus at Dana Farber Cancer Institute and Harvard Medical School today announced via a global press release that,

“Led by Harvard Medical School assistant professors Andrea Richardson and Zhigang Charles Wang, the investigators identified two genes that, when abnormally active, enabled cancer cells to resist the effects of the anthracyclines. This class of agents includes doxorubicin, daunorubicin, and epirubicin, which are often used as adjuvant therapy in breast cancer.”

What this means is that before this announcement, anthracycline class of chemotherapeutics – doxorubicin (Adriamycin), daunorubicin, epirubicin, idarubicin – have been used indiscriminately on everyone for four decades to treat many types of cancer, including leukemia, lymphoma, sarcomas and carcinomas, The standard method of administration had been to use the highest tolerable dose (based on the patient’s suffering tolerance) every few weeks to kill all rapidly growing cells by preventing them from accurately copying their genetic material.

Bioprin…a remarkable compound… comparable to cisplatin… showed no side effects.

However, a significantly high percentage of women have experienced a recurrence of cancer. They have had to continue their treatments often with even more toxic and dangerous chemotherapeutic agents.

Now, based on a woman’s gene markers, a tremendous amount of pain and suffering can now be totally avoided. If a women tests positively for these two genes, she will not be treated with anthracycline class of chemotherapeutics since they will eventually be proven ineffective anyways.

The report explains that out of 85 cases, 20% tested positive for these two genes. And that 20% was anthracycline chemotherapy resistant.

Further testing showed that stronger chemotherapeutical agents paclitaxel and cisplatin were however effective on this 20% group. Scientists are working on developing testing that will predict if patients should be treated directly with paclitaxel and cisplatin; skipping anthracycline class of chemotherapeutics completely.

FCC Disclosure: This blog is produced by JBNI, the producer of “Bioprin.” Dana Farber Cancer Institute / Harvard Medical School Ph.D.s called it a, “remarkable compound” and reported that it was “comparable to cisplatin” yet showed no side effects.

Posted via web from HerbHolist: Health Myths You Still Believe

These statements have not been evaluated by the Food and Drug Administration. This blog post of any of JBNI’s formulas are not intended to diagnose, treat, cure or prevent any disease. Consult your physician before making any decisions about your health care. Bioprin, along with all of JBNI’s formulas are intended to support the efficacy of current prescription and your body’s ability to mitigate any side effects resulting from the treatments you are currently undergoing.